InflaRx Halts Vilobelimab Phase 3 Trial for Pyoderma Gangrenosum

InflaRx ( (IFRX) ) just unveiled an announcement.

On May 28, 2025, InflaRx announced that the Independent Data Monitoring Committee recommended stopping the Phase 3 trial of vilobelimab for pyoderma gangrenosum due to futility, based on data from the first 30 patients. The company plans to discontinue development in this indication and focus on INF904, with upcoming Phase 2a data in chronic spontaneous urticaria and hidradenitis suppurativa. Despite this, vilobelimab, marketed as GOHIBIC, remains available in the U.S. under Emergency Use Authorization for COVID-19 treatment and has marketing authorization in the EU for SARS-CoV-2-induced acute respiratory distress syndrome.

The most recent analyst rating on (IFRX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on InflaRx stock, see the IFRX Stock Forecast page.

Spark’s Take on IFRX Stock

According to Spark, TipRanks’ AI Analyst, IFRX is a Underperform.

InflaRx’s overall stock score is low, primarily due to significant financial challenges, including ongoing losses and cash flow issues. While short-term technical indicators suggest some upward momentum, the overbought signals and poor valuation metrics temper optimism. Investors should be cautious due to the company’s persistent operational struggles and lack of profitability.

To see Spark’s full report on IFRX stock, click here.

More about InflaRx

InflaRx N.V. is a biopharmaceutical company that specializes in developing anti-inflammatory therapeutics targeting the complement system. The company focuses on creating inhibitors for the complement activation factor C5a and its receptor C5aR, with its lead product candidate being vilobelimab, an anti-C5a monoclonal antibody. InflaRx also develops INF904, an oral inhibitor of C5aR signaling, and operates out of Jena and Munich, Germany, as well as Ann Arbor, Michigan, USA.

Average Trading Volume: 300,694

Technical Sentiment Signal: Buy

Current Market Cap: $122.2M

For a thorough assessment of IFRX stock, go to TipRanks’ Stock Analysis page.